Price T Rowe Associates Inc Puma Biotechnology, Inc. Transaction History
Price T Rowe Associates Inc
- $867 Billion
- Q4 2024
A detailed history of Price T Rowe Associates Inc transactions in Puma Biotechnology, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 19,083 shares of PBYI stock, worth $54,577. This represents 0.0% of its overall portfolio holdings.
Number of Shares
19,083
Previous 13,357
42.87%
Holding current value
$54,577
Previous $35,000
68.57%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding PBYI
# of Institutions
107Shares Held
32.2MCall Options Held
43.4KPut Options Held
3.7K-
Vanguard Group Inc Valley Forge, PA3.64MShares$10.4 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.57MShares$10.2 Million0.0% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA3.06MShares$8.76 Million0.42% of portfolio
-
Acorn Capital Advisors, LLC New York, NY2.45MShares$7.01 Million6.49% of portfolio
-
Acadian Asset Management LLC Boston, MA1.97MShares$5.64 Million0.02% of portfolio
About PUMA BIOTECHNOLOGY, INC.
- Ticker PBYI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,556,000
- Market Cap $130M
- Description
- Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...